U.S. Food, 2026-11-20: The FDA's own application register shows three mebendazole applications ever approved: Janssen's NDA 017481 (Vermox 100 mg, 1974, discontinued) and NDA 208398 (Vermox Chewable 500 mg, 2016, discontinued), and Impax/Amneal's ANDA 073580 (Emverm, 1995, still marketed).
"application_number": "ANDA073580"
U.S. Food, 2026-11-20: The FDA's own application register shows three mebendazole applications ever approved: Janssen's NDA 017481 (Vermox 100 mg, 1974, discontinued) and NDA 208398 (Vermox Chewable 500 mg, 2016, discontinued), and Impax/Amneal's ANDA 073580 (Emverm, 1995, still marketed). Record field (JSON values from the openFDA drugsfda endpoint, access date, page undated (record read 2026-11-20), not prose): NDA017481 JANSSEN PHARMS, VERMOX, TABLET, CHEWABLE, ORAL, marketing_status Discontinued; NDA208398 JANSSEN PHARMS, VERMOX, TABLET, CHEWABLE, ORAL, Discontinued, ORIG submission 2016-10-19 type 'Type 5 – New Formulation or New Manufacturer'; ANDA073580 IMPAX LABS INC, EMVERM, TABLET, CHEWABLE, ORAL, Prescription, ORIG submission 1995-01-04. Note the register still names Impax Laboratories as the ANDA holder while the current label names Amneal Pharmaceuticals LLC (Amneal acquired Impax in 2018). Emverm is therefore a generic ANDA, not a new drug: its label carries the 1974 'Initial U.S. Approval' line because that is the molecule's first approval date.
